# US 2024/0197738 A1 · Compound 7ai in treating ewing sarcoma by inhibiting otud7a

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197738 A1
- Document ID: US20240197738A1
- Status: Published application
- Kind: A1
- Application number: 18/284,416
- Filed: 2022-04-05
- Published: 2024-06-20
- Earliest claimed: 2021-04-05
- Assignees: The University of North Carolina at Chapel Hill; Atomwise Inc.
- Applicants: The University of North Carolina at Chapel Hill; Atomwise Inc.
- Inventors: Pengda Liu; Siyuan Su; Ian Jonathan Davis; Christian Laggner
- Web page: https://patentgrep.com/patent/US20240197738A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D 487/04: Ortho-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compositions for targeting 0TUD7A, the compositions having a component sufficient to block and/or reduce OTUD7A-mediated deubiquitination of EWS-FLI1 in a cell. The component can be 7Ai and variants thereof. The compositions can be used to treat Ewing sarcoma (EWS). Methods of using the disclosed compositions are also disclosed, including methods of treating EWS in a subject.t

## Claims

### Claim 1

A composition for targeting OTUD7A, the composition comprising a component sufficient to block and/or reduce OTUD7A-mediated deubiquitination of EWS-FLI1 in a cell, wherein the component comprises 7Ai and variants thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the component is a catalytic inhibitor, wherein the catalytic inhibitor inhibits the catalytic activity of OTUD7A.

### Claim 3 (depends on 1)

The composition of claim 1, wherein blocking and/or reducing OTUD7A-mediated deubiquitination of EWS-FLI1 substantially destabilizes EWS-FLI1 in the cell, wherein the stability of EWS-FLI1 is reduced by about 50% or more.

### Claim at position 4

4-6. (canceled)

### Claim 7 (depends on 1)

The composition of claim 1, wherein 7Ai comprises the following structure:

### Claim 8 (depends on 1)

The composition of claim 1, wherein 7Ai is in the composition at a concentration sufficient to provide a dosage of about 10 μM when administered to a subject.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition comprises a delivery vehicle for the component, wherein the delivery vehicle is an expression vector, nanoparticle, liposome or vesicle.

### Claim 10

(canceled)

### Claim 11

An OTUD7A catalytic inhibitor, the catalytic inhibitor comprising a 7Ai compound or variant thereof.

### Claim 12 (depends on 11)

The catalytic inhibitor of claim 11, wherein the catalytic inhibitor is configured to substantially limit Ewing sarcoma growth in vivo by degrading EWS-FLI1.

### Claim 13 (depends on 11)

The catalytic inhibitor of claim 11, wherein the 7Ai compound comprises the following structure:

### Claim 14

A method of treating Ewing sarcoma and related conditions, the method comprising administering to a subject having Ewing sarcoma or suspected of suffering from Ewing sarcoma a composition comprising a component targeting a fusion oncoprotein, wherein the fusion oncoprotein comprises EWS-FLIT, wherein the component comprises 7Ai or variant thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the component targets OTUD7A.

### Claim 16 (depends on 14)

The method of claim 14, wherein the component blocks and or reduces OTUD7A-mediated deubiquitination of EWS-FLI1 in a cell in the subject.

### Claim 17 (depends on 14)

The method of claim 14, wherein the component is a catalytic inhibitor, wherein the catalytic inhibitor inhibits the catalytic activity of OTUD7A.

### Claim 18 (depends on 14)

The method of claim 14, wherein blocking and/or reducing OTUD7A-mediated deubiquitination of EWS-FLI1 substantially destabilizes EWS-FLI1, wherein the stability of EWS-FLI1 is reduced by about 50% or more.

### Claim 19 (depends on 14)

The method of claim 14, wherein the component substantially reduces EWS-FLI1 levels in the cell.

### Claim 20 (depends on 14)

The method of claim 14, wherein the 7Ai comprises the following structure:

### Claim 21 (depends on 14)

The method of claim 14, wherein the subject is suffering from a cancer or is believed to be suffering from a cancer, wherein the cancer is characterized by FLIT overexpression or dependent on FLI1 for proliferation.

### Claim 22 (depends on 14)

The method of claim 14, wherein 7Ai is in the composition at a concentration sufficient to provide a dosage of about 10 μM when administered to a subject.

### Claim 23 (depends on 14)

The method of claim 14, wherein the composition comprises a delivery vehicle for the component, wherein the delivery vehicle is an expression vector, nanoparticle, liposome or vesicle.

### Claim 24 (depends on 14)

The method of claim 14, wherein the composition is co-administered to the subject with at least one chemotherapeutic drug.

### Claim at position 23

25-32. (canceled)
